Ventyx Biosciences, Inc. (VTYX)
Ventyx Biosciences, Inc.
12790 El Camino Real
Suite 200
San Diego, CA 92130
United States
760 593 4832
https://ventyxbio.com
Sector(es): Healthcare
Industria: Biotechnology
Empleados a tiempo completo: 73
Ejecutivos clave
| Nombre | Título | Pagar | Ejecutado | Año de nacimiento |
|---|---|---|---|---|
| Dr. Sheila K. Gujrathi M.D. | Executive Chairperson | 125k | N/D | 1970 |
| Dr. Raju S. Mohan Ph.D. | Founder, CEO, President & Director | 905.29k | N/D | 1958 |
| Dr. John M. Nuss Ph.D. | Chief Scientific Officer | 630.63k | N/D | 1959 |
| Mr. Roy M. Gonzales CPA, M.B.A. | Interim Principal Financial Officer & Principal Accounting Officer | N/D | N/D | 1975 |
| Mr. Matthew Richard Moore | Chief Operating Officer | N/D | N/D | 1973 |
| Dr. Mark S. Forman M.D., Ph.D. | Chief Medical Officer | N/D | N/D | 1966 |
Descripción
Ventyx Biosciences, Inc., a clinical-stage biopharmaceutical company, develops small molecule product candidates to address a range of inflammatory diseases. The company's lead clinical product candidate is VTX958, a selective allosteric tyrosine kinase type 2 inhibitor for psoriasis, psoriatic arthritis, and Crohn's disease. It is also developing VTX002, a sphingosine 1 phosphate receptor modulator that is in Phase II clinical trials for the treatment of ulcerative colitis; and VTX2735, a peripheral-targeted NOD-like receptor protein 3 inflammasome inhibitor to treat patients with cryopyrin-associated periodic syndrome. In addition, the company develops VTX3232, a CNS-penetrant NLRP3 inhibitor. Ventyx Biosciences, Inc. was incorporated in 2018 and is based in San Diego, California.
Gestión corporativa
La calificación ISS Governance QuickScore de Ventyx Biosciences, Inc. a partir del 1 de octubre de 2024 es 9. Las puntuaciones principales son Auditoría: 2; Junta: 9; Derechos del accionista: 8; Compensación: 10.
